The Mountain View, Calif.-based sequencing-as-a-service company Complete Genomics "plans to sell up to an estimated $86.3 million in an initial public offering," according to the Wall Street Journal, and is "staking its claim to the ticker symbol GNOM" on the Nasdaq, the San Jose Mercury News reports.